Hepatocyte growth factor (HGF) is associated with subclinical and clinical atherosclerosis. However, the significance of change in HGF and development of atherosclerotic disease is unknown. In a large and diverse population-based cohort, we report that change in the biomarker HGF is an independent predictor of incident CHD.
Bibliographical noteFunding Information:
This research was supported by the NIH contracts N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169 from the National Heart, Lung, and Blood Institute (NHLBI) at NIH and by grants UL1-TR-000040 and UL1-TR-001079 from National Center for Research Resources at NIH. Funding for adhesion protein levels was provided by the NHLBI by grant R01 HL98077. Dr. Bell was supported by the NIH T32 Training Grant HL07111-40.
© 2019 Elsevier Inc.